Shanghai Proton and Heavy Ion Center
上海市质子重离子医院
Listed for 8 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Shanghai Proton and Heavy Ion Center
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌0 papers led
- Hepatocellular carcinoma肝细胞癌2 papers led
- Lung cancer肺癌6 papers led3 open trials led
- Pancreatic cancer胰腺癌0 papers led1 open trial led
- Breast cancer乳腺癌1 paper led3 open trials led
- Glioma胶质瘤2 papers led
- Chordoma脊索瘤0 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Osteosarcoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌10 hospitals in Shanghai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingIndividualized Neck Cervical Irradiation Prophylaxis Trial of NPC
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07303023
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChengdu, Chongqing, Hangzhou, Shanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status8
- Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma
- Individualized Carbon-Ion Radiotherapy for Patients With Locally Recurrent Nasopharyngeal Carcinoma
- Proton Versus Photon Radiotherapy for Nasopharyngeal Carcinoma
- Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma
- Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma
- Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma
- Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
Cancer
Hepatocellular carcinoma
肝细胞癌Led 2 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.01%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Shanghai for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Cancer
Lung cancer
肺癌Led 6 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.03%.
- Open trials as a site
- 0
- led by another institution
22 hospitals in Shanghai for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingCarbon Ion Therapy for Peripheral Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT05613452
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingCarbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06311981
Age 75 years to Not stated (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingRandomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06205927
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led6
- Risk Factors for Synchronous Lung Metastasis in Squamous Cell Carcinoma of Hypopharynx.
- Intensity-modulated proton and carbon-ion radiotherapy using a fixed-beam system for locally advanced lung cancer: dosimetric comparison with x-ray radiotherapy and normal tissue complication probability (NTCP) evaluation.
- Clinico-biological-radiomics (CBR) based machine learning for improving the diagnostic accuracy of FDG-PET false-positive lymph nodes in lung cancer.
- Utilization of Diaphragm Motion to Predict the Displacement of Liver Tumors for Patients Treated with Carbon ion Radiotherapy.
- Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report.
- Machine learning based on clinico-biological features integrated 18F-FDG PET/CT radiomics for distinguishing squamous cell carcinoma from adenocarcinoma of lung.
Cancer
Pancreatic cancer
胰腺癌19 hospitals in Shanghai for pancreatic cancer192 hospitals in China for pancreatic cancer
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingAblative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
- Phase
- N/A
- Started
- 2022-07
- Posted
- Registry
- NCT05424159
Age 18 years to 80 years (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status6
- Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer
- Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
- Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
- Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
- Carbon Ion RT for Locally Advanced Pancreatic Cancer
- Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
Cancer
Breast cancer
乳腺癌Led 1 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.01%.
- Open trials as a site
- 0
- led by another institution
19 hospitals in Shanghai for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06677879
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingUltra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07135661
Age 40 years to Not stated; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingA Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
- Phase
- Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05692674
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status5
- A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
- Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
- A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
- A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer
- Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position
Cancer
Glioma
胶质瘤Led 2 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.03%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
17 hospitals in Shanghai for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Chordoma
脊索瘤Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
14 hospitals in Shanghai for chordoma84 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
21 hospitals in Shanghai for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Getting in touch
Name card to show staff or a driver
上海市质子重离子医院
Shanghai Proton and Heavy Ion Center
上海
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
No hospital-level ROR record matched.